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Abstract 
Cardiac troponins constitute essential components of the cardiac contractile apparatus and are 
released into the bloodstream following cardiomyocyte injury. Because of their cardiac 
specificity, cardiac troponin I or T are the recommended biomarkers for diagnosing acute 
myocardial infarction. However, cardiac troponin concentrations also frequently increase 
acutely after strenuous prolonged exercise, making the interpretation of cardiac troponin test 
results in patients presenting with acute chest pain challenging. This acute troponin response 
following exercise is commonly considered to be physiological and without adverse long-term 
consequences, but the possibility of exercise-induced, minor myocardial injury that may 
become clinically relevant if repeated over decades, has not been ruled out. Attempts to 
biochemically differentiate between physiological cardiac troponin release versus release after 
acute ischemic myocardial injury has so far proved largely unsuccessful, but future 
measurement of specific troponin fragments could be promising. Cardiac troponins also provide 
strong prognostic information across the spectrum of cardiovascular (CV) disease (CVD). In 
the chronic setting, low-level elevation of cardiac troponins has been associated with adverse 
outcome, and concentrations even within the normal range provide independent information 
concerning risk of developing heart failure (HF) and CVD death. Exercise exerts many 
beneficial effects on the CV system, and longitudinal observational data from epidemiological 
studies suggest that higher physical activity (PA) is associated with lower concentrations of 
cardiac troponins. Conversely, a sedentary life-style has been associated with higher cardiac 
troponin concentrations and a parallel increase in the risk of HF. Serial measurement of cardiac 
troponins using high sensitivity assays for monitoring the effect of life-style intervention, 
including PA appears promising. 
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Alphabetical list of abbreviations: 
AMI: Acute myocardial infarction AMI 
CAD: Coronary artery disease CAD 
CCTA: Coronary computer tomography angiography 
CRF: Cardiorespiratory fitness  
CV: Cardiovascular  
CVD: Cardiovascular disease  
HF: heart failure  
HFpEF: Heart failure with preserved ejection fraction 
METs: Metabolic equivalents of task  
MRI: Magnetic resonance imaging  
NSTEMI: non-ST-segment MI  
PA: Physical activity  










Physical fitness and cardiovascular (CV) health are closely linked.  Data from large population-
based, prospective observational studies has shown that maintaining or improving fitness is 
associated with lower CV disease (CVD) risk (1). Conversely, low cardiorespiratory fitness 
(CRF) has been linked to increased risk of heart failure (HF) and HF related deaths (2-4). Even 
though multiple studies have shown CV benefits related to physical activity (PA), controversy 
still remains concerning the optimal PA level for CV maintaining health, and a potential U- 
shaped relation between the life-long PA exposure and CVD events has been suggested (5, 6) 
(Figure 1).  For instance, chronic structural myocardial disease, such as myocardial fibrosis or 
atrial fibrillation may be more frequent in long-practicing endurance athletes (7-10), suggesting 
that long-term, repetitive strenuous PA may be harmful for the myocardium in some 
individuals. Other studies have shown a dose-dependent relation between life-long exposure to 
PA and the burden of coronary atherosclerotic plaques (11, 12). These findings are, however, 
nuanced in a very recent publication. A large population study followed 21 178 healthy men 
for ten years, demonstrating that the HRs for CV death and all-cause mortality were lowest at 
the highest PA level (> 3000 metabolic equivalents of task (METs) minutes pr. week) (13, 14). 
This was in spite of a slight increase in the observed plaque burden in the high PA group.  
 
CV biomarkers are essential tools for diagnostic and prognostic assessment of patients with 
suspected or established CVD. In contemporary cardiology, cardiac troponins, the prototypical 
biomarkers of myocardial injury, are routinely used for confirming or excluding a diagnosis of 
acute myocardial infarction (AMI). During the past decade, there have been notable 
improvements in troponin assay sensitivity and precision.  In contrast to earlier generation 
assays, which did not detect measurable concentrations in healthy subjects or patients with 
stable coronary artery disease (CAD), the high sensitivity assays that are currently used in 
clinical practice can reliably measure circulating cardiac troponin concentrations in the majority 
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of an adult general population. In other words, from previously being a largely quantitative test 
(“troponin positive or negative”), current high sensitivity assay are capable of accurately 
measuring very low circulating concentrations of cardiac troponin T and cardiac troponin I. 
This means that not only major myocardial necrosis, but also minor myocardial injury can be 
detected by serial measurements.  
Exercise can elicit an acute release of cardiac troponins. Traditionally, this has been interpreted 
as a physiological response. However, the magnitude of the troponin response depends on the 
intensity and duration of PA, and the long-term prognostic significance of repetitive, exercise-
induced, troponin release is not known. Conversely, chronically increased circulating 
concentrations of cardiac troponins are related to a poor prognosis (15-18). If changes in PA 
level can modulate troponin concentrations, serial troponin measurements may serve as an 
index of change in CVD risk.  
In this review, we will provide an overview of the acute effect of exercise and the chronic 
effects of PA on the cardiac troponins and discuss the potential clinical implications of these 
biomarkers responses.   
 
Cardiac Troponins, Biomarkers of Acute Myocardial Injury  
Troponins are protein complexes attached to tropomyosin that are present in all skeletal and 
cardiac muscle cells. Tropomyosin covers the actin-myosin binding sites on the actin filaments 
and blocks muscle contraction. During calcium influx into the muscle cell, calcium binds to the 
troponin complex initiating a conformational change leading to exposure of the binding sites 
with actin-myosin binding and muscle contraction as a result. Troponin has three different 
subunits (troponin T, troponin I and troponin C), of which two exist in cardiac specific forms; 
cardiac troponin T and cardiac troponin I. Detection of acutely increasing concentrations of 
cardiac troponins in the circulation is a sign of acute myocardial injury, but provides no 
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etiologic information as to the underling condition or disease causing the release. Accordingly, 
although cardiac troponins are most commonly used to detect acute ischemic injury, a variety 
of other primary cardiac (e.g. myocarditis, cardiac arrhythmias) and non-cardiac (e.g. sepsis, 
burns, exercise) conditions may be associated with acutely increased circulating concentrations 
of cardiac troponins.   
 
Exercise-Induced Troponin Response 
Exercise is commonly associated with an acute increase in circulating concentrations of cardiac 
troponins. The first article describing acute elevation of troponin concentrations in some 
individuals following strenuous physical exercise was published in 1987 (19). As PA was 
generally believed to be healthy and cardiac troponins were interpreted as biomarkers of 
cardiomyocyte necrosis only, this observation initially seemed paradoxical. If a physiological 
troponin response exists, this has the potential to confound the association between cardiac 
troponin elevation and the presence of myocardial ischemia or injury used in the emergency 
room to diagnose AMI or identify patients with a poor prognosis. More than hundred studies 
have been performed to further elucidate the troponin response during exercise, showing 
conflicting data regarding prevalence and expected concentrations, most likely due to 
heterogeneity in study design (e.g. different intensity and duration of exercise, differences in 
age, training experience and risk factors of participants, different timing of the samples and 
different assays used) (20, 21).  
Several important observations were made during this initial phase to characterize exercise-
induced troponin release. In a landmark study, Turer et al showed that following rapid pacing 
troponin concentrations in the coronary sinus increased to a similar extent in patients with and 
without significant CAD and regardless of pacing-induced lactate production (i.e. interpreted 
as a sign of ischemia) (22) (figure 2). Healthy individuals had lower baseline cardiac troponin 
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values than patients with CAD, but appeared to have an increase of similar magnitude following 
pacing.  Other studies of patients with suspected CAD undergoing myocardial perfusion 
imaging examining the association between baseline and exercise-induced troponin levels and 
the presence and magnitude of reversible perfusion defects have shown diverging results (23, 
24). Although patients with reversible ischemia have higher baseline troponin levels, in most 
studies the exercise-induced increase is not consistently higher in patients with ischemia. In 
2008 Middelton et al conducted a small but important study including nine well-trained men 
who were sampled every 30 minutes during and up to 24 hours after, a marathon run. Troponin 
elevation was evident in all participants, even though a contemporary, and not a high-sensitivity 
troponin T assay was used (25) (Figure 3). Subsequent studies using high sensitivity assays 
have confirmed this finding (26). Taken together, these findings suggest that physiological 
factors e.g. increased heart rate in patients without CAD, can cause acute release of cardiac 
troponins into the blood stream regardless of the presence or absence of myocardial ischemia. 
However, it also raises the question how to define and establish the presence or absence of 
minimal myocardial necrosis. Current imaging modalities lack the sensitivity required to detect 
necrosis that can be detected by a minor, transient increase in cardiac troponin concentrations. 
Accordingly, it is not surprising that imaging studies, including cardiac magnetic resonance 
(CMR) studies, have been unable to confirm development of myocardial necrosis after 
endurance exercise. For instance, in 17 runners no evidence of myocardial inflammation or 
other indices of necrosis was evident after a marathon (27). On the other hand, transient post-
exercise ventricular dysfunction has been shown to correlate with troponin increase after intense 
endurance exercise (28, 29). It is conceivable that regular repetition of strenuous activities far 
beyond regular intensity over several decades eventually may lead to permanent myocardial 






Troponin Profiles as a Tool to Differentiate Between Causes of Release 
Troponin profiles may differ according to the underlying mechanism leading to the release. 
Thus, after transmural AMI the troponin release pattern is characterized by a prolonged phase 
(>48 hours) of elevated troponin concentrations, compatible with ongoing cell fragmentation 
and necrosis (30). In contrast, after exercise troponin concentrations typically peak within a few 
hours and normalize within 1-2 days (20, 31, 32). Indeed, a recent study, showed that a marked 
and prolonged (>24 hours) troponin elevation after endurance exercise is associated with 
obstructive CAD on coronary CT angiography while troponin levels obtained immediately after 
exercise show no such association (33). Data from animal studies indicate that the troponin 
washout in minor type II non-ST-segment MI (NSTEMI) is much faster compared to what is 
expected after transmural AMI (34) and similar dynamics could be expected in patients with a 
minor type 2 NSTEMI and in healthy recreational athletes.  Another interesting observation is 
that the ratio between troponin I and troponin T seems to be higher in patients with transmural 
AMI than after endurance exercise (35).  However, the clinical implications still remain unclear 
(36). 
 
Determinants of Exercise-Induced Troponin Release 
Identifying potential determinants of troponin elevation after exercise may provide clues as to 
whether the release is physiological or not. Although results are not entirely consistent, the 
majority of studies links greater troponin increases to higher exercise intensity rather than  
exercise duration (20). Accordingly, even short term exercise, such as during exercise stress 
testing, is associated with significant increase in troponin concentrations, although levels 
typically are lower than after long-term strenuous exercise, such as bike races or marathon runs 
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(20, 23, 24, 26, 37). Concerning prior CRF, the preponderance of data seem to suggest that a 
low CRF is associated with a greater response compared to those with high CRF and extensive 
prior training experience (29, 38). A weaker troponin response associated with higher CRF may 
be interpreted as a possible adaptive process to repetitive reversible injury (39). Concerning the 
impact of age on the magnitude of the troponin response, data are conflicting (20).  
 
Mechanisms of Exercise-Induced Troponin Response  
Currently, three different main mechanisms for troponin release have been proposed: through 
injured cell membranes from viable cells, or as a result of apoptosis or necrosis (40) (Figure 4). 
The relative importance of these models for exercise-induced troponin release remains unclear. 
Traditionally, the dominating hypothesis has been that a small pool of free troponin T and 
troponin I circulates in the cytoplasm and may readily exit a viable cell through cell wounds, 
membranous blebs or microparticles following reversible cell injury. The remaining troponin 
content (> 90%) within the cardiomyocyte is bound to tropomyosin as troponin T-troponin I-
troponin C-troponin complexes that are only released after cell necrosis and subsequent 
degradation of structural protein (41). A more recent version of this hypothesis proposes that 
cardiac troponins do not actually circulate in the cytosol, but that a pool of troponin molecules 
displays a weaker affinity binding to the myofilaments (40). Cardiomyocyte stress due to 
contraction, stretching, beta-adrenergic stimulation or limited ischemia may activate proteolytic 
enzymes (e.g. calpain or caspase) or induce pH changes within the cell leading to a release of 
the loosely bound troponin molecules from the myofilaments and subsequent release through 
an injured cell membrane (40). The second possible mechanisms for exercise induced troponin 
response proposes an initiation of a cell death program leading to cardiomyocyte apoptosis (42-
44). Apoptosis has been demonstrated in patients with heart failure and is likely to occur after 
AMI (42). The increased cardiac preload and subsequent stretching of the cardiomyocytes that 
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occur during exercise has been suggested to be a trigger for apoptosis. According to a strict 
definition apoptosis should not lead to intracellular content being released into circulation, 
however, cardiomyocytes have been suggested to represent an exception from this rule. 
According to current theory, apoptotic bodies from cardiomyocytes or the entire cell break and 
release their content into circulation, instead of being engulfed by the surrounding cells (42).  
The third model for troponin release during exercise is cardiomyocyte necrosis and subsequent 
inflammation. Necrosis occurs in a situation with disrupted cell membrane, large Ca influx and 
ATP depletion. The biochemical hallmark of necrosis is an immediate and substantial troponin 
increase followed by a prolonged (>24 hours) less prominent troponin release due to slow 
washout of troponin molecules bound to degrading myofibrils from necrotic cells. This washout 
is flow-dependent and fluctuations in concentrations can therefore sometimes be observed (45). 
The observation that the troponin concentration usually normalize within 24 hours after exercise 
speaks against major necrosis as an important factor in exercise-induced troponin release but 
the resemblance with profiles observed after minor NSTEMI, means that minor necrosis cannot 
be totally excluded as a contributing mechanism.  
 
Assays Measuring Exercise- Induced Troponin Fragments 
Troponin molecules in the circulation may be modified depending on the mechanism causing 
the release. A recent publication has shown that circulating intact troponin T is detectable in 
only a few patients with AMI. After MI, troponin T is degraded in a time-dependent manner 
and two different main troponin fragments of 29 kDa and 14-18 kDa, respectively, have been 
detected (46).  Extensive and time dependent fragmentation after MI has also been 
demonstrated for troponin I (47). Mingels and colleagues further investigated circulating 
troponin molecules after endurance exercise and identified circulating troponin fragments of 
14-18 kDa only (48). A similar pattern has been seen in patients with chronic kidney disease 
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(49). The technology measuring these fragments has certain limitations, e.g. the lower limit for 
analytical sensitivity is as high as 70 ng/L (48), but future development of troponin assays 
identifying troponin fragments derived from reversible myocardial injury, apoptosis or 
cardiomyocyte necrosis would be most useful to distinguish between physiological and 
pathophysiological troponin release.  
 
Is Exercise-Induced Troponin Response Linked to Long-Term Health Outcomes?   
In the clinical interpretation of the troponin response following endurance exercise, the long-
term prognosis associated with different response patterns is obviously a key question.   Data 
relating troponin levels before or during PA to long-term clinical outcomes are unfortunately 
scarce, but in a recent study of 108 recreational marathon runners coronary plaque burden 
(measured using coronary computer tomography angiography (CCTA) and myocardial fibrosis 
(measured using magnetic resonance imaging (MRI) late gadolinium enhancement), but not the 
magnitude of the troponin I increase after the run, were associated with future CVD events (50). 
However, this was a relatively small study and the troponin I assay used was not a high 
sensitivity assay (TnI-Ultra, ADVIA Centaur XP analyser, Siemens Healthcare Diagnostics). 
Clearly, further studies in larger cohorts using high sensitivity assays are required to establish 
the prognostic value of different troponin responses after endurance exercise. 
Exercise intolerance is a cardinal feature of HF with preserved ejection fraction (HFpEF). 
Several randomized controlled trials (RCTs) performed in older patients with HF have 
demonstrated that regular exercise increases the peak oxygen uptake in patients with HFpEF 
and improves myocardial strain (51-54). In a recently published study, troponin concentrations 
were more than 2-fold higher in subjects with HFpEF, both at rest and during exercise, than in 
control subjects. Furthermore, troponin T elevations during exercise correlated inversely with 
aerobic capacity (55) (figure 5). These observations indicate that aerobic capacity may 
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influence the post-exercise troponin response, raising the question whether the troponin 
response during activity may be used as indication of treatment effect in HFpEF.  
 
Cardiac Troponins as Measures of Chronic Myocardial Injury and Prognosis 
After the introduction of cardiac troponins as diagnostic tool in clinical practice, it was observed 
that some patients, e.g. with chronic kidney disease or chronic HF, had stable, low-level 
elevations in troponins (56, 57). Moreover, chronic elevation in cardiac troponins was 
associated with a high risk for CVD events and imminent death. With the introduction of high 
sensitivity assays it became clear that even cardiac troponin levels below the measurable range 
of prior assays provided strong and graded prognostic information (15, 16, 58). Accordingly, 
even in patient groups that previously rarely had detectable levels of cardiac troponins, such as 
patients with stable coronary artery disease without heart failure of in the general population, 
high-sensitivity cardiac troponins were closely associated with CVD risk, independently of 
traditional CVD risk factors and markers (15-18). Interestingly, the association between cardiac 
troponins and CVD risk is particularly strong for the incidence of HF, and less strong for 
atherothrombotic events (15, 59). In recent cardiac magnetic resonance studies, cardiac 
troponins correlate closely with the presence of non-ischemic, but not ischemic myocardial 
scars (60). Accordingly, in this context circulating cardiac troponins should be regarded as 
indices of subclinical myocardial injury rather than as an index of the severity of CAD per se. 
 
 
Are the Beneficial Effects of PA Associated with Changes in Resting Troponin Concentrations? 
Complex interactions may influence the association between PA and cardiac troponin 
concentrations. In large-scale epidemiological studies of elderly subjects from the general 
population self-reported PA has been inversely associated with troponin levels (61). Moreover, 
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in middle-aged subjects sedentary behaviour measured by an accelerometer (i.e. sedentary time 
was defined as <100 counts/min using an Actical (Phillps Respironics) activity wrist monitor) 
has been associated with higher troponin T concentrations (62). Circulating cardiac troponin 
concentrations increase with age (16, 63), and in the elderly temporal changes in physical 
activity are related with changes in troponin concentrations in that higher PA seem to attenuate 
the age-dependent increase in cardiac troponins (61). So far, data from RCTs are sparse. 
However, one recent RCT has confirmed these observational data showing that moderate 
exercise intervention in older sedentary adult slows down the age-expected increase in troponin 
T concentrations evident in control subjects (64). These findings suggest that resting troponin 
concentrations are modifiable by regular exercise programs, and future work should investigate 
whether reductions in cardiac troponins are linked to a favourable long-term prognosis. Such 
data would be of particular interest in vulnerable patient cohorts with few treatment options, 
like patients with HFpEF. 
 
Conclusions  
Cardiac troponins are released into circulation as a result of reversible cardiomyocyte cell 
membrane injury, apoptosis or necrosis. Exercise may induce acute troponin release in the 
absence of manifest cardiac pathology. The mechanisms responsible for exercise-induced 
troponin release are not fully known, but clinical and experimental data suggest acute necrosis 
as an unlikely underlying cause in most cases. The possibility of measuring troponins molecules 
that are specific for ischemia-induced necrosis would simplify diagnosis of acute coronary 
syndromes. Stable elevation of cardiac troponin suggests chronic myocardial injury, and has 
been linked to sedentary life style, low physical fitness, and increased risk of CVD in general, 
and HF in particular. Regular physical exercise leads to improvement in CRF, and even though 
limited randomized data exists, observational studies indicate that increased PA leads to 
14 
 
reduced resting troponin concentrations and possibly also a reduction in the exercise-induced 
troponin response. The clinical utility of cardiac troponin measurements for monitoring the 




























Figure 1. Relation between exposure for exercise and health risk. Reprinted with permission 











Figure 2. Time-dependent increases in troponin concentrations were measured in the coronary 
sinus during atrial pacing. Similar increase was observed in patients with and without ischemia 
(defined as lactate production) and in the presence and absence of coronary artery disease. 
Figure 1. Relation between exposure for exercise and health risk. Reprinted with permission 









Figure 3. Troponin response in 9 runners measured before, during and after a marathon run. 










Figure 4. The model shows the three different release pathways currently suggested for cardiac 













Figure 5. Relation between troponin concentration, ventricular reserve, and exercise capacity. 
Panel A: Compared with control subjects (n=20), subjects with HFpEF (n=38) displayed less 
increase in LV diastolic (e`) and systolic (s`) mitral annular tissue velocities during peak 
exercise. Panel B: Compared with subjects with HFpEF with normal troponin T at rest, those 
with elevated troponin T displayed impaired systolic reserve during peak exercise. Panel C: 
Elevated peak exercise troponin T was associated with impaired LV systolic reserve with 
exercise. Panel D: Exercise troponin T concentrations were inversely correlated with peak 
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